| NCT ID | NCT03478553 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Idiopathic Pulmonary Fibrosis (IPF) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2018-01-18 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2018-01-18 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
Eligibility Criteria
Inclusion Criteria: * Age at least 18 years old * Family member diagnosed with IPF Exclusion Criteria: \- No family member with IPF
Contact & Investigator
David A Schwartz, MD
PRINCIPAL INVESTIGATOR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT03478553 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Idiopathic Pulmonary Fibrosis (IPF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03478553 currently recruiting?
Yes, NCT03478553 is actively recruiting participants. Contact the research team at rachel.warren@cuanschutz.edu for enrollment information.
Where is the NCT03478553 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT03478553 clinical trial?
NCT03478553 is sponsored by University of Colorado, Denver. The principal investigator is David A Schwartz, MD at University of Colorado, Denver. The trial plans to enroll 1,000 participants.